StocksFundsScreenerSectorsWatchlists
HCAT

HCAT - Health Catalyst Inc Stock Price, Fair Value and News

7.66USD+0.22 (+2.96%)Delayed as of 28 Mar 2024, 10:59 am ET

Market Summary

HCAT
USD7.66+0.22
Delayedas of 28 Mar 2024, 10:59 am
2.96%

HCAT Alerts

  • 1 major insider buys recently.
  • Losses in recent quarter

HCAT Stock Price

View Fullscreen

HCAT RSI Chart

HCAT Valuation

Market Cap

435.7M

Price/Earnings (Trailing)

-3.69

Price/Sales (Trailing)

1.47

Price/Free Cashflow

-12.7

HCAT Price/Sales (Trailing)

HCAT Profitability

Return on Equity

-32.2%

Return on Assets

-16.83%

Free Cashflow Yield

-7.88%

HCAT Fundamentals

HCAT Revenue

Revenue (TTM)

295.9M

Rev. Growth (Yr)

8.56%

Rev. Growth (Qtr)

1.78%

HCAT Earnings

Earnings (TTM)

-118.1M

Earnings Growth (Yr)

15.29%

Earnings Growth (Qtr)

-37.58%

Breaking Down HCAT Revenue

52 Week Range

7.4714.37
(Low)(High)

Last 7 days

-0.1%

Last 30 days

-20.5%

Last 90 days

-18.4%

Trailing 12 Months

-33.6%

How does HCAT drawdown profile look like?

HCAT Financial Health

Current Ratio

4.42

Debt/Equity

0.62

Debt/Cashflow

-0.15

HCAT Investor Care

Shares Dilution (1Y)

4.94%

Diluted EPS (TTM)

-2.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023282.0M284.6M290.0M295.9M
2022254.2M265.2M271.8M276.2M
2021199.6M215.9M230.5M241.9M
2020164.8M171.3M179.1M188.8M
2019127.2M141.0M147.5M154.9M
2018086.2M99.4M112.6M
201700073.1M

Tracking the Latest Insider Buys and Sells of Health Catalyst Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 15, 2024
llewelyn linda
sold
-15,647
7.8043
-2,005
chief people officer
Mar 01, 2024
llewelyn linda
sold (taxes)
-27,688
8.0512
-3,439
chief people officer
Mar 01, 2024
lesueur daniel
sold (taxes)
-26,399
8.0512
-3,279
chief operating officer
Mar 01, 2024
hunt bryan truman
sold (taxes)
-94,070
8.0512
-11,684
chief financial officer
Mar 01, 2024
alger jason
acquired
-
-
70,000
chief financial officer
Mar 01, 2024
burton daniel d.
sold (taxes)
-40,038
8.0512
-4,973
chief executive officer
Mar 01, 2024
freeman kevin lee
sold (taxes)
-36,552
8.0512
-4,540
chief commercial officer
Mar 01, 2024
landry benjamin
sold (taxes)
-26,689
8.0512
-3,315
general counsel
Mar 01, 2024
alger jason
sold (taxes)
-19,918
8.0512
-2,474
chief financial officer
Mar 01, 2024
lesueur daniel
acquired
-
-
70,000
chief operating officer

1–10 of 50

Which funds bought or sold HCAT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-90.21
-6,874
676
-%
Mar 15, 2024
B. Riley Wealth Advisors, Inc.
reduced
-42.86
-14,664
19,054
-%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-14.5
-14,186,300
51,003,800
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
175
13,651,800
22,606,000
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
0.84
-21,783
260,160
-%
Feb 21, 2024
Raleigh Capital Management Inc.
added
17.29
395
5,777
-%
Feb 20, 2024
Quarry LP
reduced
-42.11
-4,883
5,500
-%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
unchanged
-
-72,595
776,405
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
11.77
10,000
435,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
369,000
369,000
0.03%

1–10 of 45

Are Funds Buying or Selling HCAT?

Are funds buying HCAT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own HCAT
No. of Funds

Unveiling Health Catalyst Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
point72 asset management, l.p.
7.2%
4,157,366
SC 13G/A
Feb 13, 2024
vanguard group inc
9.57%
5,507,972
SC 13G/A
Feb 08, 2024
wellington management group llp
5.58%
3,213,413
SC 13G
Jan 24, 2024
blackrock inc.
9.2%
5,318,571
SC 13G/A
Jul 27, 2023
point72 asset management, l.p.
5.0%
2,824,198
SC 13G
Feb 14, 2023
alliancebernstein l.p.
0.2%
134,154
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
2.9%
1,566,000
SC 13G/A
Feb 13, 2023
capital research global investors
1.0%
568,785
SC 13G/A
Feb 09, 2023
vanguard group inc
11.09%
6,069,528
SC 13G/A
Feb 06, 2023
wellington management group llp
2.53%
1,385,432
SC 13G/A

Recent SEC filings of Health Catalyst Inc

View All Filings
Date Filed Form Type Document
Mar 19, 2024
4
Insider Trading
Mar 15, 2024
144
Notice of Insider Sale Intent
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
3
Insider Trading

What is the Fair Value of HCAT?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Peers (Alternatives to Health Catalyst Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
454.6B
371.6B
-6.04% 4.38%
20.31
1.22
14.64% 11.24%
106.2B
195.3B
3.13% 30.55%
19.78
0.54
8.17% -20.79%
100.0B
357.8B
1.79% 0.39%
11.97
0.28
10.95% 93.52%
87.7B
65.0B
6.93% 30.56%
16.74
1.35
7.86% -7.11%
41.9B
154.0B
-2.30% 15.93%
15.51
0.27
6.54% 124.79%
12.6B
14.3B
11.30% 47.77%
17.56
0.88
6.59% 6.24%
12.0B
12.1B
9.73% 82.98%
17.36
0.99
4.57% 23.40%
MID-CAP
9.7B
2.3B
11.19% 28.50%
35.74
4.3
6.06% 9.17%
7.2B
2.9B
-7.72% 12.77%
-333.68
2.47
12.20% -107.93%
2.3B
3.8B
3.63% -32.94%
11.05
0.61
-27.73% -52.50%
2.3B
1.4B
3.04% 7.42%
37.6
1.65
21.19% 34.42%
SMALL-CAP
1.7B
1.1B
9.76% -2.01%
26.93
1.59
11.31% 35.83%
1.2B
3.0B
4.38% 103.39%
-6.6
0.41
6.74% 20.73%
56.3M
-
28.14% -20.98%
-3.85
-
- -12.94%
16.9M
20.7M
-2.22% -14.90%
83.48
0.82
6.53% -85.60%

Health Catalyst Inc News

Latest updates
MarketBeat • 11 hours ago
Investing.com • 19 Mar 2024 • 10:07 pm
Simply Wall St • 23 Feb 2024 • 08:00 am
Seeking Alpha • 22 Feb 2024 • 08:00 am

Health Catalyst Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue1.8%75,08473,77373,21373,86869,16268,35470,63368,08764,71661,73759,62755,84653,27947,19143,25945,11643,50139,42336,80435,21336,084
Operating Expenses11.9%63,29356,56668,39370,47867,80177,73569,21858,43875,60470,90061,89352,82565,67346,29735,77039,15335,49641,52728,45728,98130,290
  S&GA Expenses14.5%17,27115,08416,39718,56920,37325,40120,92220,81821,86320,80816,70515,65114,79314,62912,50213,48711,70514,72110,38510,47311,627
  R&D Expenses14.8%20,28817,66717,59017,08219,61420,77018,14817,14817,47916,38514,52414,34514,97813,39012,06113,08813,04313,4779,71010,02210,561
Income Taxes142.4%14359.0085.0069.0084.00156-944-3,600-149-6,658-19210124.0014.004.00-1,23699.0021.0011.0011.007.00
Net Income-37.6%-30,312-22,032-32,613-33,190-35,782-45,735-33,428-22,458-48,992-40,014-35,834-28,370-43,018-27,326-27,183-17,490-14,266-21,416-10,694-13,720-13,575
Net Income Margin6.3%-0.40*-0.43*-0.52*-0.53*-0.50*-0.55*-0.55*-0.58*-0.63*-0.64*-0.62*----------
Free Cashflow-750.6%-19,2962,966-11,981-6,005-15,236-13,225-9,778802-10,398-7,049-7,101----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Assets-1.6%702713723752752776811825832846563571578571466309302320140111
  Current Assets-3.7%39340841143542844346548250851532132533032339725026428095.0067.00
    Cash Equivalents11.9%10695.0011613311612417719819327620513392.0011110461.0018.0052.0021.0028.00
  Net PPE-1.5%26.0026.0026.0026.0026.0025.0027.0025.0023.0021.0020.0019.0013.005.004.004.004.004.004.005.00
  Goodwill3982.5%1915.0018618618618618618017017062.0010810810818.0018.004.004.004.00-
Liabilities1.3%33533133334732733634234431029628730230227123210510211311276.00
  Current Liabilities5.7%89.0084.0087.0010283.0091.0090.0093.0093.0026325525988.0066.0050.0050.0048.0053.0051.0042.00
  Long Term Debt0.2%228228227227227226226225181---16916616348.0048.0048.0048.0019.00
    LT Debt, Current--------------------1.00
    LT Debt, Non Current0.2%228228227227227226226225181---16916616348.0048.0048.0048.0019.00
Shareholder's Equity-4.0%367382390405425440469481522549276269276300234204201207--
  Retained Earnings-2.8%-1,117-1,086-1,064-1,032-999-963-917-884-878-829-789-754-725-682-655-628-610-596-557-374
  Additional Paid-In Capital------1,4041,3871,3651,4011,3791,0661,0231,002982889832811803--
Shares Outstanding2.2%58.0057.0057.0056.0055.0054.0053.0053.0047.0049.0045.00---------
Float---688---783---2,500---946-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-711.3%-19,0413,115-11,574-5,580-14,821-12,031-9,5761,158-9,775-5,360-4,845-3,143-4,141-4,487-751-16,769-13,061-5,482-8,417-5,224-12,986
  Share Based Compensation-8.6%13,01114,23214,62913,88418,74817,30417,93218,12016,42117,48717,72713,51010,6749,4969,0468,7414,8169,9741,3981,6561,311
Cashflow From Investing220.4%29,917-24,858-7,41522,6496,256-33,182-13,7511,656-76,683-172,79472,42337,376-21,905-3,976-106,83050,146-22,070-157,318-1,558-28,6564,694
Cashflow From Financing-62.0%3951,0401,20293.00637-7,5391,9012,3883,916248,8334,8896,4466,74015,503150,7799,5871,098194,040-1,41437,6578,619
  Buy Backs----1,808-8,393---------------

HCAT Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Revenue[1]$ 295,938$ 276,236$ 241,926
Cost of revenue, excluding depreciation and amortization:   
Total cost of revenue, excluding depreciation and amortization[1]164,105143,049124,354
Operating expenses:   
Sales and marketing67,32187,51475,027
Research and development72,62775,68062,733
General and administrative76,55961,70185,934
Depreciation and amortization42,22348,29737,528
Total operating expenses258,730273,192261,222
Loss from operations(126,897)(140,005)(143,650)
Interest and other income (expense), net9,106(1,678)(16,458)
Loss before income taxes(117,791)(141,683)(160,108)
Income tax provision (benefit)356(4,280)(6,898)
Net loss$ (118,147)$ (137,403)$ (153,210)
Net loss per share, basic (in USD per share)$ (2.09)$ (2.56)$ (3.23)
Net loss per share, diluted (in USD per share)$ (2.09)$ (2.63)$ (3.23)
Weighted-average shares outstanding used in calculating net loss per share, basic (in shares)56,418,39753,721,70247,494,768
Weighted-average shares outstanding used in calculating net loss per share, diluted (in shares)56,418,39754,079,73247,494,768
Technology   
Revenue:   
Revenue[1]$ 187,583$ 176,288$ 147,718
Cost of revenue, excluding depreciation and amortization:   
Total cost of revenue, excluding depreciation and amortization[1]62,47456,64247,516
Professional services   
Revenue:   
Revenue[1]108,35599,94894,208
Cost of revenue, excluding depreciation and amortization:   
Total cost of revenue, excluding depreciation and amortization[1]$ 101,631$ 86,407$ 76,838
[1]Includes amounts attributable to related party transactions. See Note 18 for further details.

HCAT Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 106,276$ 116,312
Short-term investments211,452247,178
Accounts receivable, net[1]60,29047,970
Prepaid expenses and other assets15,37916,335
Total current assets393,397427,795
Property and equipment, net25,71225,928
Operating lease right-of-use assets13,92716,658
Intangible assets, net73,38492,189
Goodwill190,652185,982
Other assets4,7423,734
Total assets701,814752,286
Current liabilities:  
Accounts payable6,6414,424
Accrued liabilities23,28219,691
Deferred revenue[1]55,75354,961
Operating lease liabilities3,3583,434
Total current liabilities89,03482,510
Convertible senior notes228,034226,523
Deferred revenue, net of current portion77105
Operating lease liabilities, net of current portion17,67618,017
Other liabilities74121
Total liabilities334,895327,276
Commitments and contingencies (Notes 9 and 16)
Stockholders’ equity:  
Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2023 and 202200
Common stock, $0.001 par value per share, and additional paid-in capital; 500,000,000 shares authorized as of December 31, 2023 and 2022; 58,295,491 and 55,261,922 shares issued and outstanding as of December 31, 2023 and 2022, respectively1,484,0561,424,681
Accumulated deficit(1,117,170)(999,023)
Accumulated other comprehensive income (loss)33(648)
Total stockholders’ equity366,919425,010
Total liabilities and stockholders’ equity$ 701,814$ 752,286
[1]Includes amounts attributable to related party transactions. See Note 18 for further details
HCAT
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company offers data operating system data platform for analytics, and application development and interoperability that provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications designed to analyze the problems faced across clinical and quality, population health, and financial and operational use cases. It also provides services expertise, which include data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
 CEO
 WEBSITEwww.healthcatalyst.com
 EMPLOYEES1200

Health Catalyst Inc Frequently Asked Questions


What is the ticker symbol for Health Catalyst Inc? What does HCAT stand for in stocks?

HCAT is the stock ticker symbol of Health Catalyst Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Health Catalyst Inc (HCAT)?

As of Wed Mar 27 2024, market cap of Health Catalyst Inc is 435.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HCAT stock?

You can check HCAT's fair value in chart for subscribers.

What is the fair value of HCAT stock?

You can check HCAT's fair value in chart for subscribers. The fair value of Health Catalyst Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Health Catalyst Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HCAT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Health Catalyst Inc a good stock to buy?

The fair value guage provides a quick view whether HCAT is over valued or under valued. Whether Health Catalyst Inc is cheap or expensive depends on the assumptions which impact Health Catalyst Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HCAT.

What is Health Catalyst Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, HCAT's PE ratio (Price to Earnings) is -3.69 and Price to Sales (PS) ratio is 1.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HCAT PE ratio will change depending on the future growth rate expectations of investors.